Biotest (BIO-FF)


Biotest stock research in summary

biotest.de


Latest Obermatt Ranks

Country Germany
Industry Biotechnology
Index CDAX, SDAX
Size class X-Small

April 7, 2017. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Gold Winner CEO

Top 10 Stock






 

Research History: Biotest

STOCK RESEARCH SUMMARY 2014 2015 2016 2017
STOCK VALUE RANKS
50
59
46
33
STOCK GROWTH RANKS
63
6
52
55
STOCK SAFETY RANKS
58
39
20
71
COMBINED STOCK RANKS
65
65
25
13

Last update of Combined Rank: 7-Apr-2017

Historic Biotest stock analysis based on the Obermatt Method. The higher the rank, the better is Biotest in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2014 2015 2016 2017
PRICE VS. REVENUES (P/S)
75
83
74
65
PRICE VS. PROFITS (P/E)
37
60
15
8
PRICE VS. CAPITAL (Market-to-Book)
37
62
65
76
DIVIDEND YIELD
36
45
33
30
CONSOLIDATED RANK: VALUE
50
59
46
33

Last update of Value Rank: 7-Apr-2017

Biotest stock analysis in respect to important value ratios. The higher the rank, the lower the value ratio; except for dividend yield where the rank is higher the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2014 2015 2016 2017
REVENUE GROWTH
74
20
52
53
PROFIT GROWTH
33
3
97
82
STOCK RETURNS
57
3
4
75
CONSOLIDATED RANK: GROWTH
63
6
52
55

Financial reporting date of Growth Rank: 30-Sep-2016

Biotest stock analysis in respect to important growth metrics. The higher the rank, the higher the growth and returns.


Safety Metrics in Detail

SAFETY METRICS 2014 2015 2016 2017
LEVERAGE
23
15
20
18
REFINANCING
78
LIQUIDITY
82
73
47
76
CONSOLIDATED RANK: SAFETY
58
39
20
71

Financial reporting date of Safety Rank: 1-Jan-2017

Biotest stock analysis in respect ot important safety metrics. The higher the rank, the lower the leverage and the more cash is available to service the debt.

Stock analysis by the purely finance fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Biotest (BIO-FF) from April 7, 2017.